GLOBE

The GLOBE score for patients with Primary Biliary Cholangitis (PBC)

The GLOBE score is an internationally relevant and validated risk assessment tool, able to accurately stratify PBC patients to high and low risk.

Age, years at initiation of UDCA therapy
Total bilirubin level, µmol/L or mg/dl after one year of UDCA therapy		Upper limit of normal:
Alkaline phosphatase level, U/L after one year of UDCA therapy		Upper limit of normal:
Albumin, g/L after one year of UDCA therapy		Lower limit of normal:
Platelets, x 10⁹/L after one year of UDCA therapy

Interpretation of the GLOBE score:

Patients with a GLOBE score corresponding with an estimated transplant-free survival comparable with an age- and sex-matched population are at low risk for future adverse events and patients with a GLOBE score corresponding with a transplant-free survival that significantly deviates from an age- and sex-matched population may benefit from new therapies

Data of an age- and sex-matched population, a population with a life-expectancy comparable with that of other countries participating in the Global PBC Study Group, were retrieved from a Dutch registry (Statistics Netherlands, www.cbs.nl).

The GLOBE score uses age-specific thresholds beyond which survival significantly deviates from an age- and sex matched general population. In subgroups of patients aged 66 years, age-specific GLOBE-score thresholds beyond which survival significantly deviates from matched individuals are 0.52, 0.01, 0.60, 1.01 and 1.69, respectively.